Johnson and Johnson has proposed a 5.5 billion dollar settlement to resolve a long-running legal battle over its talc-based products, according to a report by LancasterOnline. The offer represents one of the most significant moves yet in a case that has stretched across years and involved tens of thousands of plaintiffs who claim the company's products caused cancer.
The lawsuits center on allegations that talc products, including the company's well-known baby powder, contained asbestos and contributed to ovarian cancer and mesothelioma in some users. Johnson and Johnson has consistently denied that its talc products were unsafe or caused cancer, but the volume of litigation and court losses pushed the company to seek a resolution.
The proposed 5.5 billion dollar figure is meant to cover claimants who filed suit alleging harm from the products. The settlement, if approved, would mark the end of what LancasterOnline described as a marathon legal fight, one that included multiple bankruptcy filings by Johnson and Johnson subsidiaries as a legal strategy to manage the claims.
That bankruptcy strategy drew sharp criticism from plaintiff attorneys and consumer advocates, who argued it was an attempt to limit payouts to cancer victims. Courts ultimately blocked some of those maneuvers, keeping pressure on the company to negotiate directly with claimants.
Johnson and Johnson stopped selling its talc-based baby powder in the United States and Canada in 2020, citing what it called a decline in demand driven by what it described as misinformation. The company later announced it would discontinue the talc formula globally by 2023, switching to a cornstarch-based alternative.
The proposed settlement still requires court approval and agreement from a sufficient number of plaintiffs to move forward. The legal process for mass tort settlements of this scale typically involves review by a federal judge and a threshold percentage of claimants accepting the terms before the deal can be finalized.
Whether the 5.5 billion dollar offer will be enough to satisfy the large and varied group of plaintiffs remains an open question. Some attorneys representing cancer patients have previously indicated that earlier settlement proposals fell short of what their clients were owed. The coming weeks and months will determine whether enough claimants accept this latest offer to bring the litigation to a close.
